Medicare coverage under Medicare Part B for pneumococcal vaccine and its administration is authorized by section 1861(s)(10)(A) of the Social Security Act and regulations at 42 CFR 410.57. 

The ACIP recommended 15-valent pneumococcal conjugate vaccine (PCV15) or 20-valent (PCV20) for PCV-naïve adults aged 65 or above on October 20, 2021. People aged 19-64 years with certain medical conditions were also a part of this recommendation.